Tremelimumab, another ICIs targeting CTLA-4, was approved in combination with durvalumab (anti-PD-L1) for treating unresectable hepatocellular carcinoma (HCC) in the USA and Japan as the first-line treatment of adults (22). Here, CD274 is linked to hepatocellular carcinoma.